Politics

EMAUKEU

EMA pushes its transparency initiative forward

24.02.2012 - The European Medicines Agency (EMA) will publish information about all drugs under review, beginning on March 1. On a monthly basis the company will issue a list disclosing the international non-proprietary name and therapeutic areas of each product under review as well as information on the type of salt, ester or derivative of the active ingredient.

Until now, EMA has published information just about orphan drugs under review. Information on other products will not be released until the Committee for Medicinal Products for Human Use (CHMP) has issued an opinion. The plan is part of the agency ’s new policy on transparency and access to documents. The agency will also assume more responsibility in the field of pharmacovigilance. Up to now, the EMA focused its post-marketing drug safety monitoring on the 568 centrally authorised medicines for human use. But as of mid-July, the EU drug watchdog will stepwise include pharmacovigilance data from nationally authorised medicines. The newly formed Pharmacovigilance Risk Assessment Committee (PRAC) will be responsible for the implementation of the new European drug safety rules.

http://www.european-biotechnology-news.com/news/news/2012-01/ema-pushes-its-transparency-initiative-forward.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SARTORIUS128.00 EUR3.85%
  • CO.DON2.29 EUR3.15%
  • WILEX3.03 EUR2.71%

FLOP

  • SANTHERA96.50 CHF-3.40%
  • PAION2.03 EUR-2.87%
  • ADDEX3.16 CHF-2.47%

TOP

  • WILEX3.03 EUR52.3%
  • SARTORIUS128.00 EUR17.9%
  • FORMYCON16.15 EUR16.2%

FLOP

  • ADDEX3.16 CHF-8.1%
  • SANTHERA96.50 CHF-6.3%
  • BIOFRONTERA1.90 EUR-5.9%

TOP

  • SANTHERA96.50 CHF2387.1%
  • WILEX3.03 EUR413.6%
  • FORMYCON16.15 EUR99.9%

FLOP

  • CYTOS0.33 CHF-89.0%
  • MOLOGEN5.65 EUR-53.5%
  • PAION2.03 EUR-53.0%

No liability assumed, Date: 26.02.2015